Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

- Francis, Prudence A., Fleming, Gini F., Burstein, Harold J., Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Ingle, James N., Coleman, Robert E., Müller, Bettina, Le Du, Fanny, Loibl, Sibylle, Winer, Eric P., Láng, István, Ruepp, Barbara, Loi, S, Colleoni, M, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation),, Ciruelos, Eva M., Bonnefoi, Hervé R., Bellet, Meritxell, Bernardo, Antonio, Climent, Miguel A., Martino, Silvana, Bermejo, Begoña

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial

- Forbes, John F., Sestak, Ivana, Holcombe, Chris, Coleman, Robert E., Jones, Louise, Ellis, Ian, Cuzick, Jack, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert